RGNX
Regenxbio Inc
8.20$
+3.4%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +6,241.4% | -22.0% | +15.0% | +173.7% | -8.4% | +42.2% | +57.3% | -25.2% | -31.1% | -18.8% | -2.8% | |
| – | +3,798.0% | -21.0% | +79.9% | +101.1% | +2.1% | +54.0% | -2.3% | -19.8% | -19.5% | -17.0% | +1.2% | |
| – | +4,727.5% | -54.1% | +87.8% | +62.0% | -8.0% | +386.8% | +2.0% | -71.9% | -64.4% | +66.6% | -40.1% | |
| – | +10,082.1% | -21.5% | +79.5% | +98.9% | -7.4% | +60.6% | -3.8% | -20.3% | -24.5% | -14.7% | -2.0% | |
| – | +13.5% | -51.7% | -54.2% | +1,715.4% | +344.3% | +12.7% | -24.6% | -6.6% | -13.0% | -18.1% | +27.0% | |
| – | – | +74.0% | +200.5% | +7.5% | +12.9% | +62.2% | +78.5% | -25.9% | – | – | – | |
| – | +0.0% | +1,633.1% | +49.9% | +105.4% | +36.1% | +44.6% | +240.8% | +7.5% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -50.2% | +140.5% | +42.3% | +123.5% | +36.4% | +592.5% | +5.8% | -9.3% | -17.3% | -21.3% | +69.8% | |
| – | -52.8% | +122.8% | +49.3% | +53.6% | +51.9% | +141.9% | +60.2% | 0.0% | -0.1% | -20.8% | +14.4% | |
| – | – | – | – | – | – | +3.3% | -29.9% | +242.3% | +17.9% | +11.8% | +506.1% | |
| – | +203.6% | +52.2% | +213.2% | -8.7% | +45.3% | +65.7% | +7.2% | +139.0% | -16.3% | +0.1% | -6.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | -25.4% | +13.2% | +178.0% | -11.5% | -16.1% | +102.3% | -32.5% | -39.6% | -16.7% | -60.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -30.2% | +187.9% | +13.1% | +22.7% | +0.1% | +1.6% | +17.8% | -1.7% | +1.3% | +13.2% | +4.2% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.